Egetis Therapeutics
5.76 SEK
-0.17 %
Less than 1K followers
EGTX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Egetis Therapeutics
EV/S
Median 2019-2024
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 18.08 | 6.85 | 6.16 | 7.10 | 5.58 | 7.00 | 5.34 |
| Shares | 57.1 | 73.4 | 179.9 | 214.6 | 292.6 | 359.2 | 395.2 |
| Market cap | 1,032.5 | 503.4 | 1,107.6 | 1,523.6 | 1,632.5 | 2,514.7 | 2,110.2 |
| Enterprise value | 777.4 | 215.6 | 963.6 | 1,395.9 | 1,437.8 | 2,277.9 | - |
| EV/S | 9.4 | 5.3 | 42.7 | 61.8 | 25.0 | 49.4 | - |
| EV/EBITDA | neg. | neg. | neg. | neg. | neg. | neg. | - |
| EV/EBIT | neg. | neg. | neg. | neg. | neg. | neg. | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 4.22 | 0.80 | 2.10 | 3.01 | 2.99 | 5.10 | 6.23 |
| P/S | 12.5 | 12.4 | 49.0 | 67.4 | 28.3 | 54.5 | 33.8 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 90.7 % | 70.4 % | 92.6 % | 90.2 % | 71.8 % | 62.2 % | 53.0 % |
| Gearing ratio | - | - | - | - | 19.9 % | 23.2 % | 24.2 % |